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This article discusses current obstacles to the rapid development of safe and effec-
tive treatments for rare cancers, and considers measures required to overcome
these challenges. In order to develop novel clinical options for rare cancers, which
tend to remain left out of novel therapeutic development because of their paucity,
efficient recruitment of eligible patients, who tend to be widely dispersed across the
country and treated at different centers, is necessary. For this purpose, it is impor-
tant to establish rare cancer registries that are linked with clinical studies, to orga-
nize a central pathological diagnosis system and biobanks for rare cancers, and to
consolidate patients with rare cancers to facilities that can conduct clinical studies
meeting international standards. Establishing an all-Japan cooperative network is
essential. Clinical studies of rare cancers have considerable limitations in study
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design and sample size as a result of paucity of eligible patients and, as a result, the
level of confirmation of the efficacy and safety shown by the studies is relatively
low. Therefore, measures to alleviate these weaknesses inherent to external condi-
tions need to be explored. It is also important to reform the current research envi-
ronment in order to develop world-leading treatment for rare cancers, including
promotion of basic research, collaboration between industry and academia, and
improvement of the infrastructure for clinical studies. Collaboration among a wide
range of stakeholders is required to promote the clinical development of treatment
for rare cancers under a nationwide consensus.
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1 | INTRODUCTION
A rare cancer is defined as a cancer with an approximate morbidity
(incidence) of <6 per 100 000 population, which has more unsolved
clinical and therapeutic problems compared to other cancers because
of the limited number of patients.1
As for actual clinical practice for rare cancers in Japan, as a lim-
ited number of patients are dispersed across the country and treated
at different sites in different clinical areas, the patients have diffi-
culty in receiving the newest evidence-based treatment at the right
time and clinical studies are difficult to promote.2 Development of
guidelines for rare cancers also tends to be delayed compared to
more common cancers and, as a result, treatment satisfaction and
performance in patients with rare cancers have been reported to be
poorer than those in patients with more common cancers.3
However, even among more common cancers, rare variants charac-
terized by specific molecular abnormalities have been identified through
recent dramatic advances in genomic analysis technology. As a result,
cancers that have not previously been considered to be rare are now
regarded as an assembly of rare subtypes of cancer based on different
molecular abnormalities. If each of these rare subtypes required specific
diagnosis, treatment and therapeutic development, the limited number
of patients would lead to problems similar to those for rare cancers.
Although Guidance on the Clinical Development of Ultra-orphan
Drugs4 (report by Narukawa’s team, 2016) and Investigation Commit-
tee on the Desirable State of Medical Treatment and Support for Rare
Cancers1 (Hotta’s report, 2015) have been compiled as efforts to fight
rare diseases, they were not always focused on cancers or on the clin-
ical development of treatments. Herein, on the basis of the report
Issues and Proposals for the Promotion of Clinical Development for
Rare Cancers 2017 compiled by the Subcommittee on Rare Cancers5
(Chairperson, Ryuzo Ueda) under the direction of the Pharmaceuticals
and Medical Devices Agency (PMDA) Science Board (Chairperson,
Kyosuke Nagata), we discuss possible challenges in accelerating the
rapid development of treatment for rare cancers and consider mea-
sures that are required to overcome these challenges.
PMDA Science Board was established in 2012 in order to
respond to the rapid progress of medical innovations in recent years
and to properly address scientific challenges in the field of advanced
science and technology. It previously published a paper regarding
the use of non-clinical studies in the regulatory evaluation of oncol-
ogy drugs.6 In addition, reports on several other topics are indicated
on the PMDA website.7
2 | RARE CANCERS AND RARE SUBTYPES
OF CANCER
In this article, we broadly discuss rare cancers, which are defined as
both rare cancers in the narrow sense and rare subtypes of cancer.
The former is narrowly defined as an anatomically and clinicopatho-
logically recognized cancer that occurs rarely (approximate morbidity
of <6 per 100 000 population) in accordance with the report of the
Investigation Committee on the Desirable State of Medical Treat-
ment and Support for Rare Cancers1 described above.
A rare subtype of cancer is defined as a rare disease entity
extracted through identification of a specific molecular abnormality
in an anatomically and clinicopathologically recognized cancer
entity.8-10 Although rare cancers and rare subtypes of cancer are
both rare disease groups with a limited number of patients, in some
respects, they have different clinicopathological backgrounds and
require different considerations in terms of drug development and
implementation of clinical studies (Table 1).
3 | PATHOLOGICAL DIAGNOSIS AND
BIOBANK FOR RARE CANCERS
Accurate pathological diagnosis is absolutely fundamental to treat-
ment/research of rare cancers including clinical studies. However,
questions have been raised about the accuracy of pathological diag-
nosis for rare cancers because of their intrinsically unusual nature,
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shortage of expert pathologists, and the paucity of pathologists
experienced in the relevant cancer type at each institution.
For example, the rate of diagnostic agreement for sarcomas, rep-
resentative rare cancers, between expert and non-expert patholo-
gists has been reported to be 50%-70% overseas, causing
therapeutically significant diagnostic disparity in 10%-20% of
cases.11,12 In Japan, the accuracy of such pathological diagnoses in a
routine clinical setting has not been validated.
One way to address these diagnostic problems related to rare
cancers is to establish a central diagnostic system for rare cancers
to be shared by medical institutions throughout the country,
thereby improving diagnostic accuracy and facilitating required
molecular biological analyses such as next-generation sequencing.
To meet this goal, specific approaches should be considered, includ-
ing the linking of human resources and organizations virtually
through the internet, and reforming the centralization structure
without disrupting the existing one, rather than attempting to cen-
tralize human resources and organizations. Such reform of the diag-
nostic system would be expected to encourage and facilitate
enrolment of patients into registries of rare cancers, and also into
appropriate clinical studies.
Moreover, because the relationship between genomic informa-
tion and therapeutic efficacy/clinical course remains poorly under-
stood in rare cancers, archiving of biological samples (biobank) aimed
at future research or therapeutic development is essential. Use of a
reinforced national pathological diagnostic system for organization of
such rare cancer biobanks represents another important concern.
4 | RARE CANCER REGISTRY
To initiate clinical studies of rare cancers, eligible patients with rare
cancers who are widely dispersed across the country and treated at
different centers must be efficiently recruited at study sites. For this
purpose, an all-Japan patient referral system that extends beyond
individual facilities would be needed.
This approach would require information about the patients with
rare cancers who are treated at each institution. Such information
would need to have real-time immediacy (and also interactivity), in
contrast to so-called epidemiological registries. A system different
from that used for population-based epidemiological registries would
be essential for registries for clinical studies of rare cancers.
However, registries for rare cancers are expected to be used not
only for patient recruitment into clinical studies but also as an external
source of control data. If it becomes possible to leverage external con-
trol data by using the registry, the burden associated with assessment
of a new drug in clinical studies of rare cancers, which are ill-fitted
with comparator-based efficacy assessment, would also be reduced.
An example of a recent approach in Japan for addressing this prob-
lem includes the MASTER KEY Project, which has been comprehen-
sively collecting genetic and treatment information and prognostic
data for patients with rare cancers to create a large-scale basic data-
base that can be applied to clinical studies.13 Case registration for rare
subtypes of cancer has also been started through SCRUM-Japan, a
genomic screening project for lung cancer and gastrointestinal cancer,
which has been founded by more than 10 pharmaceutical companies
and organized by National Cancer Center.14 The MASTER KEY Project
and SCRUM-Japan are both oriented to construction of a large-scale
patient registry of rare cancers and rare subtypes that integrates clini-
cal and genomic information. This research is expected to establish
globally compatible rare cancer genomic data registries that could
cover future global trials.
5 | CLINICAL STUDIES OF RARE CANCERS
In clinical studies of rare cancers, study design is considerably
restricted as a result of the paucity of patients, compared to clinical
TABLE 1 Rare cancers and rare subtypes of cancer
Rare cancers in the narrow sense Rare subtypes of cancer
Definition A cancer that has been recognized as an entity anatomically
and clinicopathologically, which occurs rarely (approximate
morbidity of <6 per 100 000 population).
A rare disease group extracted through identification of a
common molecular abnormality from among a cancer type
that is anatomically and clinicopathologically recognized as an
entity.
Disease examples Soft tissue sarcoma, osteosarcoma, ocular malignancy, small
intestinal cancer, neuroendocrine tumor, central nervous
system glioma etc.
Rare fractions of lung adenocarcinoma: ALK gene translocation
(5%), RET fusion gene (1%), ROS1 gene translocation (1%), and
BRAF mutations (1%) etc.
Characteristics • In many cases, the molecular abnormality characterizing
each rare cancer type is absent or remains unknown
• It is difficult to expect that a drug targeting a single mole-
cule would show marked therapeutic efficacy
• The physician or the department in charge may not always
be specialized in cancer treatment
• In order to improve the quality of clinical practice and pro-
mote clinical research, measures including consolidation
and networking are considered to be effective
• As each rare subtype has a common molecular abnormality,
dramatic therapeutic efficacy can be expected by targeting a
single molecule
• Proof of concept for drug vs efficacy is clear
• Many of the physicians and departments in charge of the
treatment of the underlying cancers are specialized in cancer
treatment
• In order to improve the quality of clinical practice, measures
including development of guidelines are considered to be
effective
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studies of more prevalent cancers. Specifically, it is restricted in
terms of setting up a concurrent control group, selection of the pri-
mary endpoint, and establishment of the sample size (level of signifi-
cance and power). As a result of these kinds of external restrictions,
the level of confirmation of the efficacy and safety of study treat-
ment indicated by the clinical study becomes relatively low.
In the EU and USA, discussions are held at various forums to
promote development of pharmaceutical products for rare diseases
including cancers. For example, Rare Cancers Europe (RCE) initiative
presented considerations for clinical study design and alternative
endpoints for rare cancers.15 The International Rare Cancers Initia-
tive (IRCI) has highlighted characteristic approaches used in previous
clinical studies of relevant rare cancers, and proposed that a study
should be regarded as a “Phase III study” if it is meant to be defini-
tive or practice-changing, despite weakness of the trial design.16
It is important to actively discuss and implement measures to
alleviate weakness as a result of external conditions associated with
clinical studies of rare cancers as much as possible. Specifically, these
measures include: (i) the use of clinical studies based on genomic
information (umbrella/basket study) and active introduction of new
study designs including self-controlled study (such as N-of-1 study),
adaptive design, and Bayesian design (Table 2); (ii) consolidation of
study facilities/expertise and promotion of patient enrolment
through sharing of study implementation status; (iii) construction of
a system to facilitate access to clinical study information; and (iv)
construction of patient registries and a system to visualize and pro-
mote the use of such registries. In addition, investigation would be
needed on a desirable state of regulatory approval (labeled indica-
tion) based on such data.17,18
Rare cancers requiring global collaborative research are not
uncommon. In order for patients not to suffer disadvantages from
being left out of treatment opportunities, we should make every
effort to participate in and/or take the initiative in planning such glo-
bal studies. There is an urgent need for organizing the treatment/re-
search structure for rare cancers to enable participation in global
research, including consolidation of patients with rare cancers at facili-
ties where precision could be controlled at an international level.
However, as the low level of confirmation of the efficacy and
safety of the study treatment cannot completely be overcome by
the above measures, it is also important to organize the scheme and
regulations to continuously review clinical usefulness of the treat-
ment, including use of a conditional early approval system premised
on planning and implementation of post-marketing special safety
measures and active use of real-world data including various medical
information databases and patient registries.
However, from the standpoint of the developer of pharmaceuti-
cal products, the level of predictability of the clinical data package
for regulatory approval has a major effect on decision-making of the
development (whether or not to start the development, and priority
and timing). For this purpose, guidance documents etc. should be
organized to describe conditions and situations where restrictions on
the study design may be alleviated, such as acceptance of single-arm
study design, use of an alternative endpoint such as the response
rate, or increased probability of type 1 and 2 errors in clinical studies
of rare cancers.
In addition, for regulatory approval of these products, it is impor-
tant to actively transmit information to society and obtain under-
standing regarding the presence of disadvantages associated with
the approval based on limited information (that the efficacy and
safety are not highly reliable), even though there may be major
advantages, especially in the field of life-threatening cancer, of
prompt delivery of pharmaceutical products. It must be said that
there is no completely correct answer for the development and
assessment of pharmaceutical products.
TABLE 2 Study designs applicable for rare cancer clinical trials
Study design Outline of the design
Umbrella study A method in which a clinical study platform (umbrella) with genomic analysis for patient selection is constructed, and the patients
are assigned to multiple arms (rare fractions) according to actionable driver mutations and receive a matched molecular targeting
drug in order to assess them simultaneously. Examples include NCI-MATCH by the NCI in USA
Basket study A method in which patients with common actionable driver mutations across organs (rare fractions of each organ cancer) are
collected to promote the development of a drug corresponding to the relevant genomic abnormality. The aim is to obtain a
therapeutic indication across organs based on a specific genomic abnormality. Examples include a clinical study of BRAF inhibitor in
cancers with BRAF mutations and a clinical study of an immune checkpoint inhibitor for cancers with abnormalities in DNA repair
(microsatellite instability-positive: MSI-H or dMMR).
N-of-1 study A study in which multiple treatments are applied to 1 patient at different times to compare the effects of these treatments.
Although an assessment can be made in a small number of subjects (rare cancers, rare fractions) by comparing the treatments in
the same individual (under the same conditions), it has limitations similar to those of a cross-over study
Adaptive design A study design in which specific factors are changed based on the data obtained during the study, as planned in advance (selection
of dose groups, change in the probability of assignment to a specific treatment group, change in the sample size etc.)
Bayesian design An assessment can be carried out with a relatively small number of subjects by introducing a prior distribution that represents
biological findings and/or data of previous research to a parameter such as therapeutic efficacy etc. Unlike conventional statistical
inference (hypothesis testing and confidence interval by the frequentist approach), consistent inference procedures and criteria on
therapeutic efficacy may be applied consecutively across analysis time points (without adjustment for the multiplicity of analysis),
based on the posterior distribution combining the prior distribution and study data. It can also be applied to umbrella, basket, or N-
of-1 studies, as well as those with adaptive designs
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6 | APPLICATION OF INNOVATIVE
SCIENTIFIC TECHNOLOGIES
It is expected that innovative scientific technologies including next-
generation sequencing, induced pluripotent stem (iPS) cells,
immunotherapy, gene therapy and cell-based therapy would consid-
erably change the development of pharmaceutical products for rare
cancers.
6.1 | Next-generation sequencing technology
Innovation in sequencing technology has enabled decoding of whole
exons, whole genome and whole transcriptomes in rare cancers,
comprehensively revealing genomic abnormalities. Representative
examples include identification of the CIC-BCOR fusion gene-posi-
tive group in small round cell tumors and identification of BRAF
gene mutations in rare hematological tumors.19 In addition, in brain
tumors for which various pathological classifications exist, it is
reported that attempts have been made to reconstruct the existing
histopathological classification based on genomic abnormalities by
systematic genomic analysis.
In contrast, the development of molecular targeting therapy has
led to the promotion of genomic medicine, whereby cases are strati-
fied and treated based on the presence or absence of a given geno-
mic abnormality, as well as clinical studies such as umbrella and
basket studies using genomic biomarkers. It is expected that rare
subtypes having relatively homogeneous genomic abnormalities will
be effectively treated with molecular targeting drugs targeting dis-
ease-specific genomic abnormalities. It will also be important in the
future to promote clinical development based on various stratifica-
tions including other molecular information/pathway activation such
as immunoprofiling, epigenomics and metabolomics, in addition to
genomic diagnosis.
6.2 | iPS cells
Rare diseases can be the target of development of pharmaceutical
products using the characteristics of iPS cells. The development of
pharmaceutical products for rare diseases is associated with many dif-
ficulties including a paucity of pathological and biological data of rele-
vant diseases and uncertainty about returns from investment for the
research and development. In this context, there are high expectations
that iPS cell technology will be able to overcome these difficulties.20
Fibrodysplasia ossificans progressiva is a very rare genetic dis-
ease characterized by generalized heterotopic ossification that pro-
gresses from childhood. It is caused by missense mutations in the
ACVR1/ALK2 gene coding the bone morphogenetic protein (BMP)
receptor, although the pathological mechanism is not known. As a
characteristic of this disease, resection of the lesion exacerbates the
symptoms and thus it is difficult to collect research materials. Togu-
chida et al overcame this problem by deriving pathologically respon-
sible cells from iPS cells established from the peripheral blood of a
patient. As a result, they discovered that an unexpected molecular
mechanism, induction of heterotopic ossification by activin-A, was
responsible for the disease and, furthermore, based on these find-
ings, they succeeded in identifying rapamycin as a drug with poten-
tial therapeutic application.21,22
Clarification of the pathology of rare cancers and subsequent
therapeutic development are associated with many difficulties: (i) dif-
ficulty obtaining clinical samples as a result of disease rarity; (ii)
delayed study of the disease as a result of its rarity and inability to
proceed to development of a therapeutic agent because the patho-
logical mechanism is unknown; and (iii) difficulty in conducting stud-
ies to validate efficacy and safety etc. These difficulties can be
overcome with iPS cells. An inexhaustible supply of iPS cells that
can replace difficult-to-obtain clinical samples is expected to make
an enormous contribution to a variety of aspects including elucida-
tion of the pathology of rare cancers, screening of candidate drugs,
and conducting clinical studies to validate efficacy/safety.
6.3 | Gene therapy, cell-based therapy and
immunotherapy
Gene therapy, cell-based therapy and immunotherapy for malignan-
cies including rare cancers have enabled remarkable clinical achieve-
ments to be made in the last few years, as though emerging from a
long tunnel. Genetically modified T-cell therapy has recently been
attempted by using the T-cell receptor (TCR therapy) approach and
the chimeric antibody receptor (CAR-T) approach against rare can-
cers including malignant melanoma and synovial sarcoma.23,24 The
development of virotherapy, which destroys tumors using genetically
engineered viruses, has also been promoted in recent years.25 In
addition, development has recently been promoted for immunother-
apy targeting somatic genes with malignant mutations, called
neoantigens, and clinical studies of combination immunotherapy and
gene therapy are now being started.
Future advances in molecular/pathological elucidation of rare
cancers may lead to further progress in the development of new
gene therapy, cell-based therapy, and immunotherapy, as well as
their clinical applications. For rare subtypes characterized by com-
mon genetic abnormalities or common tumor antigens etc., therapeu-
tic efficacy of gene therapy, cell-based therapy, and immunotherapy
may well be expected.
7 | EXPERIENCES OF JAPAN CHILDREN ’S
CANCER GROUP (JCCG)
Pediatric cancers, which comprise various tumor types, are also con-
sidered to be rare cancers. In the field of pediatric cancer, efforts
have long been made by separate clinical research groups for individ-
ual tumor types. In 2015, based on a decision to organize clinical
research groups for pediatric cancers into an all-Japan organization,
the Japan Children’s Cancer Group (JCCG) was established.26At pre-
sent, nearly 90% of patients newly diagnosed with pediatric cancer
in Japan every year (about 2500 cases annually) are treated at
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JCCG-affiliated centers. JCCG is operated as a community by func-
tionally integrating treatment facilities and universities located
around the country to organize infrastructure/support centers to aid
optimization of research and improve quality, including a central
diagnostic center, data center and biobank.
The philosophy of JCCG that any single facility- or group-based
structures are inadequate given the regional expansion and rarity of
the cases and that a collaborative clinical research structure to con-
solidate rare cases under an all-Japan structure is needed, as well as
the strategy of JCCG to promote basic research and clinical studies
using patients accumulated through the central diagnostic service,
may directly serve as an excellent model for clinical development of
other rare cancer treatment.
8 | FUTURE PERSPECTIVES
We reviewed some concerns related to therapeutic development for
rare cancers that should be addressed, clarifying the definition of
rare cancers.
The first concern is the development of an efficient structure for
treatment and clinical research of rare cancers. As patients will be
disadvantaged by the absence of accurate pathological diagnosis,
there is an urgent need to improve the accuracy of pathological
diagnosis of rare cancers. In the field of rare cancers, it is also partic-
ularly important to organize biobanks to facilitate new research and
therapeutic development and to construct case registries to facilitate
clinical studies. In the context of present clinical settings for rare
cancer treatment where a limited number of patients are dispersed
across the country and treated at different locations in different clin-
ical departments, achieving the above points is a major challenge.
The second concern is the problem of the evaluation method in
clinical studies of rare cancers. Compared to clinical studies of diseases
with many patients, there are considerable restrictions in clinical stud-
ies of rare cancers in terms of design and sample size and, as a result,
the level of confirmation of the efficacy and safety shown by the study
is relatively low.7 Measures should be taken to alleviate weaknesses of
these studies as a result of external conditions.
As measures to overcome these problems and promote the
development of effective treatments and drugs for rare cancers, we
propose the following specific action goals from the aspects of: (i)
acquisition of accurate patient information and establishment of
developmental bases; (ii) use of biomarkers; (iii) environmental con-
siderations for promotion of therapeutic development for rare can-
cers; and (iv) rearrangement of the evaluation methods (Table 3).
The Ministry of Health, Labour and Welfare (MHLW) is also
working to promote construction of the base for drug development
through various policies. The Act on the Safety of Regenerative
Medicine27 was enacted in November 2014, together with The Act
on Securing Quality, Efficacy and Safety of Pharmaceuticals, Medical
Devices, Regenerative and Cellular Therapy Products, Gene Therapy
Products, and Cosmetics.28 In addition, a new approval system for
regenerative medicine, including conditional approval, was started in
line with the practical application of regenerative medicine. In Octo-
ber 2017, a conditional early approval system was also started for
pharmaceutical products.29
In order to provide effective treatments to patients with rare
cancers as early as possible, advocacy of the patient association is
also very important. Advocacy refers to “increasing awareness about
an important and interesting issue”. The patient association must
have a clear vision of current health care, participate actively in dis-
cussions, and cooperate with various associations working towards
the same goal, particularly in the field of rare cancers with a limited
number of patients.
Recent advances made in the field of life science have been
remarkable; from the perspective of clinical development for rare
TABLE 3 Proposed action goals for promoting clinical development for rare cancers
Objective Action goals
Acquisition of accurate patient
information and establishment of
developmental bases
(a) Construction of an all-Japan cooperative network
(b) Organization of a central pathological diagnosis system and biobank
(c) Promotion of rare cancer registries that are linked with clinical studies
(d) Consolidation of patients with rare cancers to facilities that can conduct clinical studies meeting interna-
tional standards
Use of biomarkers (a) Promotion of clinical studies that use biomarkers (genomic information etc.)
(b) Promotion of development of companion diagnostics
Environmental considerations for
promotion of therapeutic
development for rare cancers
(a) Promotion of basic research for rare cancers
(b) Promotion of industrial participation, and industry-academia collaborative work
(c) Establishment of infrastructure for clinical studies of rare cancers including centralization of institutional
review board
(d) Education and development of clinicians specializing in rare cancers
(e) Participation of patient advocates, and discussions involving the whole nation
Rearrangement of evaluation methods (a) Listing of approaches for various measures to alleviate weakness as a result of external conditions on
the study design
(b) Provision of ideas to improve the efficacy and efficiency of clinical trial consultation
(c) Provision of ideas for the method of collection of post-marketing safety and efficacy information and
systematic confirmation of the results
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cancer treatment, there has been new progress which previously
could not have been imagined. Although the concepts discussed in
the present article will not always be easy to realize, effective and
substantive therapeutic development for rare cancers should eventu-
ally become possible through nationwide consensus-based coopera-
tion and active exchange of ideas among a wide range of
stakeholders in the field, including scientific societies, health-care
professionals, patient advocates, pharmaceutical companies and reg-
ulatory authorities.
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